中国实用外科杂志2024，Vol.44Issue(1)：85-88,4.DOI:10.19538/j.cjps.issn1005-2208.2024.01.14
NCCN胰腺癌临床实践指南(2023.V2版)更新解读
Updates and interpretations of the NCCN Clinical Practice Guide 2ed version 2023 on pancreatic adenocarcinoma
摘要
Abstract
Pancreatic ductal adenocarcinoma has poor biological behavior and poor prognosis.How to standardize its diagnosis and treatment to further improve postoperative survival rate and long-term quality of life is a challenge faced by pancreatic surgeons.The National Comprehensive Cancer Network(NCCN)guidelines released the second edition of pancreatic cancer diagnosis and treatment guidelines this year on June 19,2023.Compared with the previous version,the new version of the guidelines has made the following updates:the NALIRIFOX protocol has officially entered the first-line treatment of locally advanced and metastatic pancreatic cancer;the functional status score is divided into good(0-1),intermediate(2),and poor(3-4);some new drugs have been included in the scope of targeted treatment for pancreatic cancer,the overall treatment tends to be precise,comprehensive and effective.The NCCN guidelines wield authoritative influence globally and the anticipation for further evidence-based medicine to emerge in the future is expected to standardize the treatment of pancreatic cancer.关键词
胰腺导管腺癌/美国国立综合癌症网络/精准医学Key words
pancreatic ductal adenocarcinoma/national comprehensive cancer network(NCCN)/precision medicine分类
医药卫生引用本文复制引用
白睿,孙备..NCCN胰腺癌临床实践指南(2023.V2版)更新解读[J].中国实用外科杂志,2024,44(1):85-88,4.基金项目
国家自然科学基金项目(No.82070658,No.82270665) （No.82070658,No.82270665）
黑龙江省自然科学基金团队项目(No.TD2021H001) （No.TD2021H001）
